Guardant Health, Inc. filed a current report on Form 8-K on November 3, 2026, disclosing that on November 2, 2026, its Board of Directors approved performance-based restricted stock unit grants to Co-Chief Executive Officers Helmy Eltoukhy and AmirAli Talasaz under the company's 2018 Incentive Award Plan.

Key Highlights

  • Grant size: Each Co-CEO received 465,413 PSUs at target, for a combined target total of 930,826 PSUs.
  • Performance periods: 25% of target PSUs are tied to a three-year period ending May 31, 2029; the remaining 75% are tied to a five-year period ending May 31, 2031.
  • Payout range: Earned PSUs range from 0% of target (below 40th percentile relative TSR) to 250% of target (at or above the 90th percentile), with no above-target shares earned if absolute TSR is negative.
  • Post-vest holding requirements: Shares from the 3-Year PSUs are generally locked until May 31, 2030; 50% of net after-tax shares from the 5-Year PSUs are locked until November 30, 2031.
  • Benchmark: Performance is measured as total shareholder return relative to constituents of the S&P 500 Index over each applicable period.
  • Historical TSR cited: According to the filing, the company delivered a total shareholder return of 275% over the last three fiscal years, outperforming the Nasdaq Biotechnology, Russell 3000, and S&P 500 indices over the same period.

Performance Conditions and Structure of the PSU Awards for Eltoukhy and Talasaz

According to the filing, the independent members of Guardant Health's Board of Directors approved the PSU Awards on November 2, 2026. The awards are described as "100% performance-based," with vesting determined solely by the company's total shareholder return relative to the S&P 500 Index constituents. The filing states that the Board designed the awards to align the Co-CEOs' pay outcomes with "sustained long-term value creation" and to incentivize performance over the next five years. Common Stock is listed on The Nasdaq Global Select Market under the symbol GH (NASDAQ:GH).

The filing sets out a detailed payout schedule. For each performance period, PSUs are earned at 0% of target if relative TSR falls below the 40th percentile, 50% at the 40th percentile, 100% at the 55th percentile, 150% at the 75th percentile, and 250% at or above the 90th percentile, with straight-line interpolation applied between thresholds. In no event may more than 250% of the Target PSUs vest. The filing also specifies that if the company's absolute TSR for a performance period is negative, earned PSUs for that period are capped at 100% of target regardless of relative performance.

A carry-forward feature is also disclosed: if the company's relative TSR for the three-year period falls below the 55th percentile, unearned 3-Year PSUs remain outstanding and may be earned at the end of the five-year period, but only if relative TSR for that period reaches or exceeds the 75th percentile. Upon a qualifying termination not connected to a change in control, a pro-rated portion of Target PSUs remains eligible based on actual performance through the termination date. In the event of a change in control, PSUs are deemed earned at the greater of target or actual performance measured to that date, subject to pro-ration if the change in control occurs on or before May 31, 2027.

What Was Disclosed

Guardant Health disclosed the approval of performance-based RSU grants of 465,413 PSUs each to Co-CEOs Helmy Eltoukhy and AmirAli Talasaz, with vesting tied exclusively to relative total shareholder return versus the S&P 500 Index over three-year and five-year periods beginning June 1, 2026.